Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 28 Feb 2018 Planned number of patients changed from 80 to 83.
- 28 Feb 2018 Planned End Date changed from 1 Dec 2026 to 1 Mar 2026.
- 28 Feb 2018 Planned primary completion date changed from 1 Dec 2022 to 1 Mar 2022.